IPXL Share Price

Open 13.60 Change Price %
High 14.35 1 Day 0.45 3.32
Low 13.60 1 Week 0.65 4.87
Close 14.00 1 Month 1.30 10.24
Volume 1761674 1 Year -20.85 -59.83
52 Week High 35.24
52 Week Low 7.75
IPXL Important Levels
Resistance 2 14.70
Resistance 1 14.41
Pivot 13.98
Support 1 13.59
Support 2 13.30
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
SIRI 5.11 -1.73%
STX 42.01 -16.83%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
CMLS 0.28 21.74%
ZAZA 0.06 20.00%
CONN 17.50 18.24%
CONN 17.50 18.24%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
PGRX 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Impax Laboratories, Inc. (NASDAQ: IPXL)

IPXL Technical Analysis 2
As on 26th Apr 2017 IPXL Share Price closed @ 14.00 and we RECOMMEND Sell for LONG-TERM with Stoploss of 19.88 & Strong Buy for SHORT-TERM with Stoploss of 12.04 we also expect STOCK to react on Following IMPORTANT LEVELS.
IPXL Target for April
1st Target up-side 15.62
2nd Target up-side 17.7
3rd Target up-side 19.78
1st Target down-side 9.68
2nd Target down-side 7.6
3rd Target down-side 5.52
IPXL Other Details
Segment EQ
Market Capital 1367854592.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.impaxlabs.com
IPXL Address
IPXL
30831 Huntwood Avenue
Hayward, CA 94544
United States
Phone: 510-476-2000
Fax: 510-471-3200
Interactive Technical Analysis Chart Impax Laboratories, Inc. ( IPXL NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Impax Laboratories, Inc.
IPXL Business Profile
Impax Laboratories Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products, referred to as generics, in addition to the development and marketing of branded products. The Company operates in two segments: Global Pharmaceuticals Division (Global Division) and the Impax Pharmaceuticals Division (Impax Division). The Global Division concentrates its efforts on the development, manufacture, sale and distribution of the Company's generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under their established drug names. The Impax Division is engaged in the development of brand pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Impax Division is also engaged in the sale and distribution of Zomig (zolmitriptan) products.